Skip to main content
    O

    Onconetix Inc (ONCO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.91
    -0.30 (-9.35%)

    Market Cap: $2.15M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Onconetix Inc (ONCO) Financials: Revenue, Profit and Cash Flow

    Updated Aug 13, 2026. Financial statements from company filings, amounts in US dollars.

    Onconetix reported revenue of $815.37K for the fiscal year ended Dec 31, 2025, down 67.7% from the year before. That year, net income was -$14.03M with a net margin of -1721.0%, operating cash flow was -$9.68M and free cash flow was -$9.68M. The quarter ended Jun 30, 2026 had revenue of $17.12K and net income of -$2.87M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$815.37K-67.7%77.6%-778.2%-1721.0%
    Dec 2024$2.52M+4217.3%41.8%-2238.0%-2325.2%
    Dec 2023$58.47KN/A-1927.9%-61634.5%-63986.5%
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$815.37K$2.52M$58.47K$0$0$0N/A
    Cost of revenue$182.46K$1.47M$1.19M$6.75K$4.89K$3.06K$573
    Gross profit$632.91K$1.06M-$1.13M-$6.75K-$4.89K-$3.06K-$573
    Research and development$66.13K$154.36K$1.95M$4.13M$1.33M$524.91K$60.17K
    Operating income-$6.34M-$56.49M-$36.03M-$13.48M-$3.42M-$1.62M-$880.23K
    Net income-$14.03M-$58.69M-$37.41M-$13.42M-$3.42M-$1.60M-$821.91K
    EBITDAN/AN/AN/A-$13.41M-$3.41M-$1.60M-$821.34K
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$17.12K$21.46K$303.60K$303.65K$106.49K$101.63K$711.98K$406.86K$704.85K$700.43K$58.47K$0
    Gross profit$4.30K-$1.66K$247.68K$268.89K$70.50K$45.83K$659.97K$105.41K$100.72K$189.00KN/A-$1.62K
    Operating income-$2.73M-$2.09M-$1.28M-$2.07M-$1.34M-$1.65M-$1.97M-$2.65M-$13.62M-$11.08M-$7.36M-$4.49M
    Net income-$2.87M-$4.21M$5.67M-$8.78M-$2.37M-$8.55M-$29.44M-$3.83M-$14.31M-$11.12M-$22.35M-$5.35M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $24.41K by $5.20M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$24.93M$28.18M$87.52M$26.31M$3.08M$4.81M$6.08M
    Current assets$6.07M$950.27K$5.84M$26.26M$3.07M$4.60M$6.06M
    Cash and equivalents$5.22M$646.50K$4.55M$25.75M$1.93M$4.31M$6.05M
    Total liabilities$9.16M$18.57M$86.11M$3.92M$1.64M$78.31K$82.62K
    Short-term debt$24.41K$9.45M$9.69MN/AN/AN/AN/A
    Long-term debtN/AN/A$118.86KN/AN/AN/AN/A
    Shareholder equity$15.76M$9.61M-$5.60M$22.39M$1.45M$4.73M$6.00M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$16.43M$14.83M$24.93M$19.68M$19.12M$18.78M$28.18M$61.92M$59.46M$75.03M$87.52M$27.88M
    Total liabilities$2.96M$3.08M$9.16M$16.30M$13.21M$14.26M$18.57M$20.90M$23.96M$89.53M$86.11M$17.65M
    Cash and equivalents$5.94M$3.72M$5.22M$836.56K$283.51K$1.58M$646.50K$341.50K$930.54K$4.46M$4.55M$7.65M
    Shareholder equity$13.47M$11.75M$15.76M$3.37M$5.91M$4.52M$9.61M$33.91M$28.43M-$21.53M-$5.60M$10.24M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$9.68M-$10.50M-$13.58M-$8.68M-$2.04M-$1.73M-$825.13K
    Capital expenditures$0$28.47K$55.04K$9.34K$1.92K$11.79K$4.50K
    Free cash flow-$9.68M-$10.52M-$13.64M-$8.68M-$2.05M-$1.74M-$829.63K
    Dividends paid$409.51K$206.40KN/AN/AN/AN/AN/A
    Investing cash flowN/A-$28.47K-$8.65M-$32.66K-$1.92K-$11.79K-$4.50K
    Financing cash flow$14.45M$6.74M$1.04M$32.53M-$334.19K$0$6.88M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$1.92M-$2.12M-$3.09M-$3.18M-$1.41M-$2.00M-$917.65K-$1.15M-$3.20M-$5.23M-$4.31M-$3.04M
    Capital expenditures$0$0$3$1$0$3.87K$3.87K$2.31K$17.70K$4.58K$0$51.74K
    Free cash flow-$1.92M-$2.12M-$3.09M-$3.18M-$1.41M-$2.00M-$921.52K-$1.15M-$3.22M-$5.24M-$4.31M-$3.09M
    Last 12 quarters

    Frequently Asked Questions About ONCO

    What is Onconetix's annual revenue?

    Onconetix reported revenue of $815.37K for the fiscal year ended Dec 31, 2025.

    How fast is Onconetix's revenue growing?

    Revenue was down 67.7% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Onconetix profitable?

    No. Onconetix reported net income of -$14.03M for the fiscal year ended Dec 31, 2025, with a net margin of -1721.0%.

    How much free cash flow does ONCO generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$9.68M minus capital expenditures of $0 produced free cash flow of -$9.68M.

    How much debt does Onconetix have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $24.41K and cash and equivalents of $5.22M.